Ocular Rosacea Clinical Trial
Official title:
Randomized, Open Label, Prospective Study on the Efficacy and Safety of Dextenza Compared to Topical Fluorometholone in Patients With Ocular Rosacea (ROSE Study)
Verified date | June 2023 |
Source | Eye Associates of Central Texas |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
To determine patient preference and treatment outcomes with an intracanalicular dexamethasone (0.4mg) insert compared to a standard steroid drop regimen in the contralateral eye for the treatment of ocular rosacea.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | November 29, 2022 |
Est. primary completion date | November 29, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Be at least 18 years of age, any gender or race - Provide written informed consent - Sign the HIPAA form - Attend all study visits - Take all study medications as directed - Be willing to avoid all disallowed medications - Be willing to avoid all contact lens wear between Dextenza insertion (Visit 2) and Post-op 1 month visit (Visit 3) - Have a best-corrected visual acuity (BCVA) or greater than or equal to 50 ETDRS letters (20/100 Snellen equivalent) or better in each eye at the screening visit. - For women of childbearing age (menarche to less than 12 months of menopause who have not undergone surgical sterilization), be willing to have a urine pregnancy test and agree to use a medically acceptable form of birth control throughout the study duration. - Have a documented diagnosis of Ocular Rosacea and exhibit typical signs or symptoms associated with the diagnosis (irritation, burning, foreign body sensation, redness, itching, inflammation, dry eye, discharge) Exclusion Criteria: - Have any allergy or other historical contraindication to the medications in the protocol - Is unable to use the study medications regularly as directed - Have any other ocular disease that could affect the subject's ability to participate in the study safely (narrow angle glaucoma, iritis, current infection, elevated intraocular pressure, history of significant steroid response with and IOP >22mmHg, punctal size less than 0.4mm or lid malformation that would preclude insertion of the Dextenza insert) - Have known history of herpetic eye disease (either active or historical) - Have a history of refractive surgery within the past 2 years - Have a history of retinal detachment, diabetic retinopathy, or active retinal disease - Is currently (within the past 7 days) using an ophthalmic steroid preparation (drop, ointment or insert form) - Is currently using ocular, topical, or systemic non-steroidal anti-inflammatory drugs (NSAIDs) - Baby aspirin (81mg) is allowed as long as a stable dose has been maintained for at least 30 days prior to Dextenza insertion and will continue to be maintained for the duration of the study - Have an active infectious disease or is currently taking (or has taken within 7 days of initiation into the study) oral antibiotics - Is actively being treated with local or systemic immunosuppression, including systemic steroids - Have a planned ocular or systemic surgery within 30 days of the placement of the Dextenza insert. - Have used a study drug or participated in a clinical study within 30 days of the beginning of this study - Is currently pregnant, planning to become pregnant, or breastfeeding - Is an employee or direct family member of an employee at the clinic site - Have a diagnosis of any significant uncontrolled illness - Have a history of alcohol or drug abuse in the past year - Is a current smoker - Have used an investigational drug or medical device within 30 days of the study or be concurrently enrolled in another investigational product trial - Have an intraocular pressure that is less than 5mmHg or greater than 22mmHg or any type of glaucoma - Is deemed unsafe for the study by the investigator |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Eye Associates of Central Texas |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in OSDI | As measured by OSDI questionnaire | Accessed at all time points (Day -30 - day -1, week 4, week 8) | |
Primary | Patient preference in treatment therapy | As measured by Adapted COMTOL questionnaire | Accessed at Week 4 | |
Secondary | Change in tear breakup time | As measured by Fluoroscein (Bioglo strip moistened with saline) placed in the inferior fornix of each eye. A cobalt blue light beam will be used to count the number of seconds between the last blink and the appearance of a dry spot or break in tear film. | Accessed at all time points (Day -30 - day -1, week 4, week 8) | |
Secondary | Change in Expression of Gland Scale | As measured by digitally compressing the lower and upper lids and quantified on a 4-point scale:
(0- all five glands, 1 - three to four glands, 2 - one to two glands, 3 - zero glands). The values will be averaged for each eye. |
Accessed at all time points (Day -30 - day -1, week 4, week 8) | |
Secondary | Change in corneal staining | As measured by the NEI/Industry Grading system | Accessed at all time points (Day -30 - day -1, week 4, week 8) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02066051 -
IPL and Meibomian Gland Expression to Treat Ocular Rosacea Ocular GVHD
|
N/A | |
Completed |
NCT03655197 -
Lipidome and Microbiome Profile of the Eye in Rosacea
|
Early Phase 1 | |
Recruiting |
NCT06466018 -
Research Into Diagnostic and Prognostic Molecular and Imaging Biomarkers of Ocular Disorders Associated With Neurovascular Deregulation: Biocor Cohort
|
N/A | |
Recruiting |
NCT05296837 -
Ocular Rosacea Biome Study
|
Phase 4 | |
Not yet recruiting |
NCT04025801 -
Heidelberg In Vivo Confocal Microscopy to Evaluate the Ocular Surface Disorders of Healthy and Diseased Individuals
|
||
Completed |
NCT03194698 -
Efficacy of IPL Treatment of Dry Eye and Ocular Rosacea
|
N/A | |
Completed |
NCT03479853 -
Clinical, Meibographic and Interferometric Evaluation of Phlyctenular Keratitis in Children - MEIBO-ROSACEE
|